Abstract
Clinical research into potential therapies for systemic lupus erythematosus (SLE) has increased over the last 2 decades, driven by the discovery of new targetable pathways, yet uncertainty persists over which patients benefit from new therapies.1 Black patients and other minoritized populations, which disproportionately experience severe disease, are underrepresented in SLE trials.2
